Related references
Note: Only part of the references are listed.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Enhancing adoptive cancer immunotherapy with VΥ2Vδ2 T cells through pulse zoledronate stimulation
Mohanad H. Nada et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug
Yoshimasa Tanaka et al.
SCIENTIFIC REPORTS (2017)
Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells
Yuki Sakai et al.
CHEMMEDCHEM (2017)
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy
Yulian Khagi et al.
CLINICAL CANCER RESEARCH (2017)
T cells for viral infections after allogeneic hematopoietic stem cell transplant
Catherine M. Bollard et al.
BLOOD (2016)
Targeting Cancer Cells with a Bisphosphonate Prodrug
Kenji Matsumoto et al.
CHEMMEDCHEM (2016)
Prospects for gene-engineered T cell immunotherapy for solid cancers
Christopher A. Klebanoff et al.
NATURE MEDICINE (2016)
Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human Vγ2Vδ2 T Cells
Hong Wang et al.
JOURNAL OF IMMUNOLOGY (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Insoluble drug delivery strategies: review of recent advances and business prospects
Sandeep Kalepu et al.
ACTA PHARMACEUTICA SINICA B (2015)
The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human Vγ9Vδ2 T Cells
Andrew Sandstrom et al.
IMMUNITY (2014)
Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer
Ikuo Wada et al.
CANCER MEDICINE (2014)
Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain
Takamichi Izumi et al.
CYTOTHERAPY (2013)
Butyrophilin 3A1 Plays an Essential Role in Prenyl Pyrophosphate Stimulation of Human V gamma 2V delta 2 T Cells
Hong Wang et al.
JOURNAL OF IMMUNOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset
Christelle Harly et al.
BLOOD (2012)
The Molecular Basis for Modulation of Human Vγ9Vδ2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies
Aparna Palakodeti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice Display a T-Effector Memory Phenotype
Niwa Ali et al.
PLOS ONE (2012)
Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours
A. J. Nicol et al.
BRITISH JOURNAL OF CANCER (2011)
Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma
Hirohito Kobayashi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Zoledronate-activated V gamma 9 gamma delta T cell-based immunotherapy is feasible and restores the impairment of gamma delta T cells in patients with solid tumors
Atsutaka Noguchi et al.
CYTOTHERAPY (2011)
Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens
Masashi Iwasaki et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Indirect Stimulation of Human Vγ2Vδ2 T Cells through Alterations in Isoprenoid Metabolism
Hong Wang et al.
JOURNAL OF IMMUNOLOGY (2011)
Adoptive Immunotherapy for Advanced Non-small Cell Lung Cancer Using Zoledronate-expanded γδ T Cells: A Phase I Clinical Study
Miki Sakamoto et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma
Yu Abe et al.
EXPERIMENTAL HEMATOLOGY (2009)
Highly Sensitive Model for Xenogenic GVHD Using Severe Immunodeficient NOG Mice
Ryoji Ito et al.
TRANSPLANTATION (2009)
Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
Jaafar Bennouna et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Preferential recognition of a microbial metabolite by human Vγ2Vδ2 T cells
Kia-Joo Puan et al.
INTERNATIONAL IMMUNOLOGY (2007)
Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells:: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens
Craig T. Morita et al.
IMMUNOLOGICAL REVIEWS (2007)
Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis
K Thompson et al.
MOLECULAR PHARMACOLOGY (2006)
Conservation of nonpeptide antigen recognition by rhesus monkey Vγ2V δ2 T cells
H Wang et al.
JOURNAL OF IMMUNOLOGY (2003)
Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells
HJ Gober et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli
M Hintz et al.
FEBS LETTERS (2001)
Share Paper
